Fosphenytoin Dosing in Acute Kidney Injury
Use standard fosphenytoin dosing (15-20 mg PE/kg loading dose) in patients with acute kidney injury, but monitor unbound (free) phenytoin levels rather than total levels, and reduce the infusion rate by 25-50% to minimize adverse effects.
Key Dosing Principles
The FDA label explicitly addresses renal impairment and provides clear guidance 1:
- Loading dose remains unchanged: Standard 15-20 mg PE/kg for status epilepticus or acute seizures
- Infusion rate modification: Reduce IV infusion rate by 25-50% in patients with renal disease
- Standard rate: ≤150 mg PE/min in adults
- Reduced rate in AKI: 75-100 mg PE/min
- Monitor unbound phenytoin concentrations: This is the critical adjustment in renal disease
Pharmacokinetic Rationale
The fraction of unbound (active) phenytoin increases significantly in AKI 1, 2. This occurs because:
- Decreased protein binding due to uremia and hypoalbuminemia
- Fosphenytoin clearance to phenytoin may increase without a proportional increase in phenytoin clearance
- This creates potential for increased frequency and severity of adverse events
Research confirms that patients with renal disease show trends toward increased fosphenytoin clearance and earlier peak phenytoin concentrations due to decreased plasma protein binding 2. While conversion efficiency remains intact, the altered protein binding creates higher free drug levels at standard total concentrations.
Monitoring Strategy
Target unbound phenytoin concentrations of 1-2 mcg/mL (rather than total levels of 10-20 mcg/mL) 1:
- Wait at least 2 hours after IV infusion completion before checking levels
- Use EDTA tubes to minimize ex vivo conversion
- Recognize that standard immunoassays may overestimate phenytoin due to cross-reactivity with fosphenytoin
Maintenance Dosing
For ongoing therapy in AKI patients (CrCl <30 mL/min):
- Reduce maintenance dose or extend dosing interval
- Pediatric data suggests 6 mg/kg/dose every 8 hours based on fat-free mass 3
- Further dose reduction needed if creatinine clearance 10-30 mL/min: Consider 75 mg once daily for treatment or 30 mg once daily for prophylaxis (extrapolated from general principles) 4, 5
Critical Safety Considerations
Slow the infusion rate - This is non-negotiable in renal impairment 1:
- Rapid infusion combined with increased unbound drug creates heightened cardiovascular risk
- Monitor for hypotension, bradycardia, and arrhythmias continuously
- Have resuscitation equipment immediately available
Avoid concurrent nephrotoxins when possible, as multiple guidelines emphasize nephrotoxin stewardship in AKI 6, 7.
Hemodialysis patients: Standard dosing can be used as phenytoin is not significantly dialyzed, but continue monitoring unbound levels 2.
Common Pitfalls
- Using total phenytoin levels: In AKI, total levels are misleading due to altered protein binding; always request unbound levels
- Not reducing infusion rate: The increased unbound fraction at standard infusion rates substantially increases cardiovascular toxicity risk
- Checking levels too early: Wait for complete conversion (2 hours post-IV) to avoid falsely elevated results from assay cross-reactivity
- Assuming dose adjustments like other renally cleared drugs: Fosphenytoin/phenytoin dosing is primarily about protein binding changes, not renal clearance
The evidence consistently supports that dose adjustments in AKI focus on infusion rate reduction and monitoring strategy rather than dramatic dose reductions 1, 8, 2.